<DOC>
	<DOCNO>NCT02252354</DOCNO>
	<brief_summary>The purpose 2 part study look TAK-385 take , broken remove body give radiolabelled oral solution ( mouth ) oral tablet ( mouth ) follow radiolabelled intravenous ( IV ) infusion ( arm vein ) .</brief_summary>
	<brief_title>TAK-385 Phase I Absorption , Distribution , Metabolism , Excretion Absolute Bioavailability Study</brief_title>
	<detailed_description>The study consist 2 part involve 12 healthy male participant . In Part 1 , 6 participant receive single 80 mg dose [ 14C ] -TAK-385 administer oral solution . In Part 2 , 6 participant receive single oral 80 mg dose TAK-385 administer two 40 mg tablet 80 μg intravenous ( vein ) dose [ 14C ] -TAK-385 ( contain 37.0kBq [ 1000 nCi ] 14C ) . This single centre study take place United Kingdom .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Signs write , informed consent form prior initiation study procedure . 2 . Is healthy male , age 18 55 ; inclusive Day1 . 3 . Is capable understand comply protocol requirement . 4 . Weighs least 50 kg body mass index ( BMI ) 18.0 35.0 kg/m^2 , inclusive Screening Day1 . 5 . In opinion investigator , good healthy condition basis prestudy physical examination , medical history , vital sign , electrocardiogram , result blood biochemistry , hematology , serology test urinalysis Screening Day 1 . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 90 day last dose . 1 . Has receive investigational compound within 45 day prior Day 1 . 2 . Has receive TAK385 previous clinical study . 3 . Has rest systolic blood pressure ≤90 mmHg ≥140 mmHg rest diastolic blood pressure ≤50 mmHg ≥90 mmHg supine position Screening Day1 . 4 . QTc ( Fridericia 's correction ) &gt; 450 msec Screening Day 1 read printout ECG produce electrocardiogram ( ECG ) equipment evaluate investigator 5 . Has active liver disease jaundice , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin ( total bilirubin ) &gt; 1.5 time upper limit normal ( ULN ) clinical laboratory test VISIT 1 2 . The participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) know history human immunodeficiency virus ( HIV ) Screening . 6 . Has rest pulse heart rate ( read ECG ) &lt; 45 beat per minute ( bpm ) &gt; 100 bpm Screening Day 1 . 7 . Has acute , clinically significant illness within 30 day prior Day 1 . 8 . Has history clinical manifestation significant metabolic ( include diabetes mellitus , hypercholesterolemia , dyslipidemia ) , hematologic , pulmonary , cardiovascular , gastrointestinal , neurological , rheumatologic , skin subcutaneous tissue disorder , infectious , hepatic , renal , urologic , immunologic , psychiatric mood disorder ( include past history suicide attempt ) , history lactose intolerance . 9 . Has family history bleeding disorder . 10 . Has current recent ( within 6 month ) history gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent heartburn , surgical intervention ) . 11 . Has irregular defecation pattern ( less one defecation per two day excessive diarrhea ) and/or history change bowel habit daily routine environment change . 12 . Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 millisievert ( mSv ) last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study 13 . Has history abdominal surgery ( except laparoscopic cholecystectomy uncomplicated appendectomy ) , thoracic nonperipheral vascular surgery within 6 month prior Day 1 . 14 . Has history cancer , basal cell Stage 1 squamous cell carcinoma skin remission least 5 year prior Day 1 . 15 . Has significant cardiovascular disease include , limited , history myocardial infarction , coronary angioplasty bypass graft , unstable angina pectoris , transient ischemic attack , clinically significant abnormal ECGs , New York Heart Association ( NYHA ) Functional Classification III IV , document cerebrovascular accident within 6 month prior Day 1 . 16 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 4 alcoholic drink per day ) within 1 year prior Screening Visit . 17 . Has use tobacco ( ie , nicotine ) product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 6 month prior Day 1 unwilling abstain product duration study positive carbon monoxide test result Screening Day 1 . 18 . Has take medication , supplement food product describe Excluded Medications section . A subject positive carbon monoxide test result Day1 . 19 . Has poor peripheral venous access . 20 . Is unwilling unable comply protocol schedule appointment 21 . Is unable understand verbal and/or write English . 22 . Is study site employee , immediate family member ( ie , spouse , parent , child , sibling ) study site employee , involve conduct study . 23 . Has receive donate 400 mL blood blood product within 45 day precede begin study plan donate blood study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>